Lancet Diabetes & Endocrinology

Papers
(The H4-Index of Lancet Diabetes & Endocrinology is 76. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-09-01 to 2024-09-01.)
ArticleCitations
Epidemiology and determinants of obesity in China760
Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study699
Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study658
COVID-19 in people with diabetes: understanding the reasons for worse outcomes654
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials616
Consensus on diagnosis and management of Cushing's disease: a guideline update386
Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study371
Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study359
Risks and burdens of incident diabetes in long COVID: a cohort study347
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial322
Obesity in children and adolescents: epidemiology, causes, assessment, and management315
Thyroid cancer incidence trends by histology in 25 countries: a population-based study305
Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials296
A global view of the interplay between non-alcoholic fatty liver disease and diabetes284
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials268
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020250
Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland241
Polycystic ovary syndrome240
Gestational diabetes: opportunities for improving maternal and child health232
Health policy and public health implications of obesity in China223
Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study221
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group221
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement218
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study213
SARS-CoV-2-related atypical thyroiditis208
Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records189
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial187
Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study186
Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study180
Bone fragility in diabetes: novel concepts and clinical implications177
COVID-19 and metabolic disease: mechanisms and clinical management166
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial162
Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study157
Towards unified and impactful policies to reduce ultra-processed food consumption and promote healthier eating153
Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England147
Vitamin D for COVID-19: a case to answer?146
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes143
Management of diabetes and hyperglycaemia in the hospital143
Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study143
RETRACTED: Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses140
Diagnosis and treatment of primary aldosteronism133
Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)129
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 126
Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial125
Clinical management and treatment of obesity in China125
Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial125
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial120
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel120
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase117
Nutritional intake and bone health116
Intake and metabolism of omega-3 and omega-6 polyunsaturated fatty acids: nutritional implications for cardiometabolic diseases114
Diabetes, metabolic disease, and telomere length111
Guideline recommendations and the positioning of newer drugs in type 2 diabetes care109
Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multic108
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial106
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial105
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial98
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial96
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial95
The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality94
Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study93
Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings93
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial93
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials92
Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction91
Menopause: a cardiometabolic transition86
Osteoporosis in men85
Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada85
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy o84
Sexual dimorphism in COVID-19: potential clinical and public health implications84
2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial81
Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial80
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial80
Diagnosis of thyroid nodules78
Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial77
Acromegaly: pathogenesis, diagnosis, and management76
Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study76
0.060216903686523